SG11201806758VA - Vcn enhancer compositions and methods of using the same - Google Patents
Vcn enhancer compositions and methods of using the sameInfo
- Publication number
- SG11201806758VA SG11201806758VA SG11201806758VA SG11201806758VA SG11201806758VA SG 11201806758V A SG11201806758V A SG 11201806758VA SG 11201806758V A SG11201806758V A SG 11201806758VA SG 11201806758V A SG11201806758V A SG 11201806758VA SG 11201806758V A SG11201806758V A SG 11201806758VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pge2
- massachusetts
- cambridge
- pct
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 239000003623 enhancer Substances 0.000 title abstract 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 abstract 5
- 229960002986 dinoprostone Drugs 0.000 abstract 4
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 abstract 4
- 241000705082 Sialia Species 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 238000001415 gene therapy Methods 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/06—Sulfuric ester hydrolases (3.1.6)
- C12Y301/06013—Iduronate-2-sulfatase (3.1.6.13)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
- C12Y304/14009—Tripeptidyl-peptidase I (3.4.14.9)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04004—Adenosine deaminase (3.5.4.4)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
w90 80 70 60 50 40- 30 20 10 0 PGE2 z 0 • 6- ! V • 4- o 2- 0 LL 4,414.4. W O 20 17 / 13957 6 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/139576 Al 17 August 2017 (17.08.2017) WIPO I PCT 111111111111110111011111111111010111110 011101111111100111111111111111111110111111 • PS • PS + PGE2 F108 100Oug/mL n F108 1000ug/mL + PGE2 • F108 62.5ug/mL n F108 62.5ug/mL + PGE2 (51) International Patent Classification: C12N 5/078 (2010.01) Cl 2N 5/074 (2010.01) (21) International Application Number: PCT/US2017/017372 (22) International Filing Date: 10 February 2017 (10.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/294,615 12 February 2016 (12.02.2016) US 62/313,571 25 March 2016 (25.03.2016) US 62/417,085 3 November 2016 (03.11.2016) US 62/429,514 2 December 2016 (02.12.2016) US (71) Applicant: BLUEBIRD BIO, INC. [US/US]; 60 Binney Street, Cambridge, Massachusetts 02141 (US). (72) Inventors: BONNER, Melissa; c/o bluebird bio, Inc., 60 Binney Street, Cambridge, Massachusetts 02141 (US). NEGRE, Olivier; c/o bluebird bio, Inc., 60 Binney Street, Cambridge, Massachusetts 02141 (US). (74) Agents: MASHRUWALA, Mary Anne et al.; Cooley LLP, 1299 Pennsylvania Avenue, NW, Suite 700, Wash- ington, District of Columbia 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, [Continued on next page] (54) Title: VCN ENHANCER COMPOSITIONS AND METHODS OF USING THE SAME (57) : The invention provides improved gene ther- apy methods and compositions. FIG. 5A *p<0.05 compared to 1 (PS - standard transduction) 8 ug/mL 82.5 ug/mL 1000 ug/mL PS F108 F108 FIG. 5B WO 2017/139576 Al MIDEDIMOHNIIMME30111001HIMMERVOIMIE TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, Published: TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, with international search report (Art. 21(3)) LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662294615P | 2016-02-12 | 2016-02-12 | |
| US201662313571P | 2016-03-25 | 2016-03-25 | |
| US201662417085P | 2016-11-03 | 2016-11-03 | |
| US201662429514P | 2016-12-02 | 2016-12-02 | |
| PCT/US2017/017372 WO2017139576A1 (en) | 2016-02-12 | 2017-02-10 | Vcn enhancer compositions and methods of using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201806758VA true SG11201806758VA (en) | 2018-09-27 |
Family
ID=59563597
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201806758VA SG11201806758VA (en) | 2016-02-12 | 2017-02-10 | Vcn enhancer compositions and methods of using the same |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP4151720A1 (en) |
| JP (1) | JP6970106B2 (en) |
| KR (1) | KR20180110112A (en) |
| CN (1) | CN108713059A (en) |
| AU (1) | AU2017217813B2 (en) |
| BR (1) | BR112018016450A2 (en) |
| CA (1) | CA3014078A1 (en) |
| IL (2) | IL310683A (en) |
| MX (1) | MX2018009750A (en) |
| RU (2) | RU2021103425A (en) |
| SG (1) | SG11201806758VA (en) |
| WO (1) | WO2017139576A1 (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201602423TA (en) * | 2011-09-30 | 2016-05-30 | Bluebird Bio Inc | Compounds For Improved Viral Transduction |
| SG10201704008RA (en) | 2012-11-27 | 2017-06-29 | The Children's Medical Center Corp | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
| CA2946309C (en) | 2014-04-25 | 2021-11-09 | Michael MILSOM | Synthetic bcl11a micrornas for treating hemoglobinopathies |
| WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
| US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
| WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
| MX2021001292A (en) * | 2018-07-30 | 2021-07-15 | Centro De Investig Energeticas Medioambientales Y Tecnologicas O A M P | Methods for gene modification of hematopoietic cells. |
| CN109055432B (en) * | 2018-08-16 | 2020-10-13 | 南京科佰生物科技有限公司 | Lentivirus infection reagent and preparation method and application thereof |
| CN109880852A (en) * | 2019-03-25 | 2019-06-14 | 和元生物技术（上海）股份有限公司 | Poloxamer P338 is improving application and method in efficiency of infection of the virus to cell |
| US20220163512A1 (en) * | 2019-03-27 | 2022-05-26 | Bluebird Bio, Inc. | Beta-thalassemia potency assay |
| US20230002784A1 (en) * | 2019-06-05 | 2023-01-05 | Orchard Therapeutics (Europe) Limited | Compositions and methods for modifying eukaryotic cells |
| US11597920B2 (en) * | 2019-06-25 | 2023-03-07 | Bio-Rad Laboratories, Inc. | Compositions and methods for enhancing reverse transcriptase activity and/or reducing the inhibition of reverse transcriptase |
| EP3766981A1 (en) | 2019-07-18 | 2021-01-20 | OZ Biosciences | Cationic poloxamers and their use in transduction |
| CN114761567A (en) * | 2019-10-16 | 2022-07-15 | 奥查德疗法(欧洲)有限公司 | Compositions and methods for modifying eukaryotic cells |
| CN113025660A (en) * | 2019-12-25 | 2021-06-25 | 深圳华大生命科学研究院 | Kit and method for transfecting human hematopoietic stem cells in vitro by lentiviruses |
| CN113621611B (en) * | 2021-04-26 | 2024-04-19 | 北京美康基免生物科技有限公司 | Marrow specific promoter and application thereof |
| CN114457119B (en) * | 2022-04-11 | 2022-08-12 | 中吉智药(南京)生物技术有限公司 | Application of lentiviral vector in preparation of drug for treating beta-thalassemia |
| CN114438130B (en) * | 2022-04-11 | 2022-07-22 | 中吉智药(南京)生物技术有限公司 | Beta-globin recombinant lentiviral vector and application thereof |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US568159A (en) | 1896-06-26 | 1896-09-22 | Veneering-machine | |
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| US5061620A (en) | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
| US5635387A (en) | 1990-04-23 | 1997-06-03 | Cellpro, Inc. | Methods and device for culturing human hematopoietic cells and their precursors |
| US5460964A (en) | 1992-04-03 | 1995-10-24 | Regents Of The University Of Minnesota | Method for culturing hematopoietic cells |
| WO1995000657A1 (en) | 1993-06-21 | 1995-01-05 | The Uab Research Foundation | Anti-sickling hemoglobin |
| US5409813A (en) | 1993-09-30 | 1995-04-25 | Systemix, Inc. | Method for mammalian cell separation from a mixture of cell populations |
| US5869039A (en) | 1993-10-15 | 1999-02-09 | Institut National De La Sante Et De La Recherche Medicale | X-linked adrenoleukodystrophy gene and corresponding protein |
| CA2199832C (en) | 1994-09-19 | 2000-08-01 | Philippe Leboulch | Anti-sickling beta-globin protein, compositions and methods for treating sickle cell disease |
| US5677136A (en) | 1994-11-14 | 1997-10-14 | Systemix, Inc. | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6057117A (en) | 1996-04-04 | 2000-05-02 | Chiron Corporation | Identification and use of selective inhibitors of glycogen synthase kinase 3 |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| FR2777909B1 (en) | 1998-04-24 | 2002-08-02 | Pasteur Institut | USE OF TRIPLEX-STRUCTURED DNA SEQUENCES FOR THE TRANSFER OF NUCLEOTID SEQUENCES IN CELLS, RECOMBINANT VECTORS CONTAINING THESE TRIPLEX SEQUENCES |
| AU2183900A (en) | 1998-12-24 | 2000-07-31 | Alcon Laboratories, Inc. | Ep4 receptor agonists for treatment of dry eye |
| US6822112B1 (en) | 1999-08-13 | 2004-11-23 | Taisho Pharmaceutical Co., Ltd. | Prostaglandin derivatives |
| AU784195B2 (en) | 1999-11-12 | 2006-02-16 | Baxter Biotech Technology S.A.R.L. | Reduced side-effect hemoglobin compositions |
| CN1272328C (en) | 1999-12-17 | 2006-08-30 | 希龙公司 | Pyrazine based inhibitors of glycogen synthase kinase 3 |
| ATE327751T1 (en) | 2000-01-31 | 2006-06-15 | Pfizer Prod Inc | USE OF PROSTAGLAND RECEPTOR 4 ACTIVATORS FOR THE TREATMENT OF ACUTE OR CHRONIC RENAL INSUFFICIENCY |
| US20020013294A1 (en) | 2000-03-31 | 2002-01-31 | Delong Mitchell Anthony | Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives |
| US6627442B1 (en) * | 2000-08-31 | 2003-09-30 | Virxsys Corporation | Methods for stable transduction of cells with hiv-derived viral vectors |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| US7994144B2 (en) * | 2001-07-10 | 2011-08-09 | Johnson & Johnson Research Pty, Limited | Process for the preparation of a composition of genetically modified hematopoietic progenitor cells |
| EP1448182A1 (en) * | 2001-11-30 | 2004-08-25 | Pfizer Products Inc. | Pharmaceutical compositions and methods for administering ep 2 receptor selective agonists |
| EP1539754A4 (en) | 2002-08-23 | 2009-02-25 | Novartis Vaccines & Diagnostic | Benzimidazole quinolinones and uses thereof |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60333487D1 (en) | 2002-12-13 | 2010-09-02 | Genetix Pharmaceuticals Inc | THERAPEUTIC RETROVIRUS VECTORS FOR GENE THERAPY |
| US6747037B1 (en) | 2003-06-06 | 2004-06-08 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| CA2585367A1 (en) | 2004-10-26 | 2006-05-04 | Allergan, Inc. | Therapeutic and delivery methods of prostaglandin ep4 agonists |
| DE102005062741A1 (en) | 2005-12-22 | 2007-06-28 | Bayer Schering Pharma Ag | Fluorenes and carbazoles as ligands of the EP2 receptor |
| CN101495623B (en) | 2006-03-24 | 2013-09-11 | 儿童医疗中心有限公司 | Method to modulate hematopoietic stem cell growth |
| AU2007314299B2 (en) * | 2006-11-03 | 2013-07-25 | Aastrom Biosciences, Inc. | Mixed cell populations for tissue repair and separation technique for cell processing |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| AU2008261901A1 (en) * | 2007-06-08 | 2008-12-18 | University Of Virginia Patent Foundation | Topical poloxamer formulations for enhancing microvascular flow: compositions and uses thereof |
| EP2341911A4 (en) * | 2008-10-01 | 2012-10-24 | Univ North Carolina | Hematopoietic protection against chemotherapeutic compounds using selective cyclin-dependent kinase 4/6 inhibitors |
| JP5836262B2 (en) | 2009-03-19 | 2015-12-24 | フェイト セラピューティクス， インコーポレイテッド | Compositions containing cyclic AMP enhancers and / or EP ligands and methods of preparing and using the same |
| KR20150029756A (en) | 2011-06-10 | 2015-03-18 | 블루버드 바이오, 인코포레이티드. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
| SG10201602423TA (en) * | 2011-09-30 | 2016-05-30 | Bluebird Bio Inc | Compounds For Improved Viral Transduction |
| ES2905250T3 (en) * | 2012-02-29 | 2022-04-07 | Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh | Retroviral transduction using poloxamers |
| WO2014026110A2 (en) * | 2012-08-10 | 2014-02-13 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| SG10201704008RA (en) | 2012-11-27 | 2017-06-29 | The Children's Medical Center Corp | Targeting Bcl11a Distal Regulatory Elements for Fetal Hemoglobin Reinduction |
| WO2016014794A1 (en) * | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
-
2017
- 2017-02-10 CA CA3014078A patent/CA3014078A1/en active Pending
- 2017-02-10 RU RU2021103425A patent/RU2021103425A/en unknown
- 2017-02-10 MX MX2018009750A patent/MX2018009750A/en unknown
- 2017-02-10 WO PCT/US2017/017372 patent/WO2017139576A1/en active Application Filing
- 2017-02-10 JP JP2018542250A patent/JP6970106B2/en active Active
- 2017-02-10 IL IL310683A patent/IL310683A/en unknown
- 2017-02-10 RU RU2018132210A patent/RU2744603C2/en active
- 2017-02-10 CN CN201780016517.1A patent/CN108713059A/en active Pending
- 2017-02-10 BR BR112018016450A patent/BR112018016450A2/en not_active IP Right Cessation
- 2017-02-10 EP EP22191258.7A patent/EP4151720A1/en active Pending
- 2017-02-10 KR KR1020187026299A patent/KR20180110112A/en unknown
- 2017-02-10 IL IL261002A patent/IL261002B1/en unknown
- 2017-02-10 EP EP17750830.6A patent/EP3414321B8/en active Active
- 2017-02-10 AU AU2017217813A patent/AU2017217813B2/en active Active
- 2017-02-10 SG SG11201806758VA patent/SG11201806758VA/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL261002A (en) | 2018-09-20 |
| JP2019504635A (en) | 2019-02-21 |
| IL261002B1 (en) | 2024-03-01 |
| EP4151720A1 (en) | 2023-03-22 |
| EP3414321B8 (en) | 2023-05-03 |
| BR112018016450A2 (en) | 2018-12-26 |
| EP3414321A4 (en) | 2019-07-10 |
| IL310683A (en) | 2024-04-01 |
| CN108713059A (en) | 2018-10-26 |
| AU2017217813A1 (en) | 2018-09-20 |
| CA3014078A1 (en) | 2017-08-17 |
| MX2018009750A (en) | 2019-02-07 |
| EP3414321B1 (en) | 2022-09-28 |
| EP3414321A1 (en) | 2018-12-19 |
| RU2021103425A (en) | 2021-02-25 |
| JP6970106B2 (en) | 2021-11-24 |
| WO2017139576A1 (en) | 2017-08-17 |
| RU2018132210A3 (en) | 2020-08-12 |
| AU2017217813B2 (en) | 2023-08-03 |
| RU2018132210A (en) | 2020-03-12 |
| RU2744603C2 (en) | 2021-03-11 |
| KR20180110112A (en) | 2018-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201806758VA (en) | Vcn enhancer compositions and methods of using the same | |
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201811405QA (en) | Improved differentiation method | |
| SG11201810179RA (en) | Novel crispr enzymes and systems | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805422WA (en) | Multivalent and multispecific ox40-binding fusion proteins | |
| SG11201804086VA (en) | Methods and compositions for nucleic acid analysis | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201907754RA (en) | Anti-phf-tau antibodies and uses thereof | |
| SG11201906301UA (en) | Methods of manufacture of nut flours and formulations for oral immunotherapy | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201809497RA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201908624SA (en) | Aryl hydrocarbon receptor antagonists and uses thereof | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201804774YA (en) | Diastereoselective synthesis of phosphate derivatives and of the gemcitabine prodrug nuc-1031 | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201803642WA (en) | Bacteria-based protein delivery | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201805170XA (en) | Cellular glycosaminoglycan compositions and methods of making and using | |
| SG11201803692PA (en) | Anti-5t4 antibodies and antibody-drug conjugates | |
| SG11201804704PA (en) | Compositions and methods for decreasing tau expression |